Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20944310 | 0.89 | TSHR (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20267365 | 0.88 | ALDH1A1 (0.50) | TSHRNPSR1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL6883767 | 0.87 | TSHR (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL286232 | 0.86 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25783698 | 0.85 | POLB (0.44) | NPSR1MAPK1SMN1; SMN2TP53THRB | |
| SCHEMBL24112451 | 0.85 | POLB (0.45) | TP53THRBALDH1A1MAPTGAA | |
| SCHEMBL5736404 | 0.84 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8303701 | 0.84 | GAA (0.48) | NPSR1MAPK1SMN1; SMN2KDM4ETP53 | |
| SCHEMBL22852764 | 0.83 | TSHR (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7992182 | 0.83 | CYP4F2 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-4659502-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | CA12 3825/4885CA1 3143/4885CA2 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.